Icure Pharmaceutical Improvement Period Ends, Delisting Review Begins, Shareholder Value at Risk
KOSDAQ Market Division announced that the 8-month improvement period granted to Icure Pharmaceutical ended on July 12, 2026, initiating the delisting review process.
The company must submit its improvement plan implementation details and expert confirmation within 15 business days, followed by a Corporate Review Committee decision on delisting within 20 business days.
While an objection process exists, the risk of trading suspension and delisting poses a serious threat to shareholder value recovery.
[AI Summary]Icure Pharmaceutical faces a critical juncture with the end of its improvement period, leading to a delisting review that amplifies financial uncertainty. With a market cap of approximately 81.5 billion KRW, 37.56 million shares outstanding, and a stock price of 2,170 KRW, potential trading suspension or delisting could inflict severe losses on current shareholders.
KOSDAQ Filing Information
Other Market Notice (Notice Of Decision On Delisting Due To Expiration Of Improvement Period)